T. Rowe Price Associates’s Apogee Therapeutics APGE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$96.2M Sell
1,143,152
-93,983
-8% -$6.83M 0.01% 623
2025
Q4
$93.4M Buy
1,237,135
+486,606
+65% +$30.6M 0.01% 640
2025
Q3
$29.8M Sell
750,529
-10,315
-1% -$394K ﹤0.01% 955
2025
Q2
$33M Sell
760,844
-61,006
-7% -$2.32M ﹤0.01% 841
2025
Q1
$30.7M Sell
821,850
-230,745
-22% -$8.92M ﹤0.01% 853
2024
Q4
$47.7M Buy
1,052,595
+294,514
+39% +$15M 0.01% 774
2024
Q3
$44.5M Sell
758,081
-10,140
-1% -$486K 0.01% 788
2024
Q2
$30.2M Sell
768,221
-402,106
-34% -$19.5M ﹤0.01% 851
2024
Q1
$77.8M Buy
1,170,327
+399,646
+52% +$17.4M 0.01% 606
2023
Q4
$21.5M Buy
770,681
+154,731
+25% +$3.1M ﹤0.01% 937
2023
Q3
$13.1M Buy
+615,950
New +$13.6M ﹤0.01% 1016

Other funds holding APGE